×
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
NASDAQ:ATHA

Athira Pharma Stock Forecast, Price & News

$3.42
+0.20 (+6.21%)
(As of 07/5/2022 03:59 PM ET)
Add
Compare
Today's Range
$3.23
$3.50
50-Day Range
$2.74
$11.01
52-Week Range
$2.53
$16.65
Volume
62,177 shs
Average Volume
2.12 million shs
Market Capitalization
$128.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.60

Athira Pharma MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
707.0% Upside
$27.60 Price Target
Short Interest
Bearish
9.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.63mentions of Athira Pharma in the last 14 days
Based on 8 Articles This Week
Insider Trading
Acquiring Shares
$836,100 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.67) to ($3.44) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.42 out of 5 stars

Medical Sector

138th out of 1,428 stocks

Biological Products, Except Diagnostic Industry

18th out of 218 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ATHA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Athira Pharma and its competitors with MarketBeat's FREE daily newsletter.

Athira Pharma logo

About Athira Pharma (NASDAQ:ATHA) Stock

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

ATHA Stock News Headlines

Athira Pharma (NASDAQ:ATHA) Cut to Hold at Stifel Nicolaus
4 Analysts Have This to Say About Athira Pharma
Athira Pharma Shares Fall To 52-Week Low - Read Why
Why Athira Pharma Stock Is Plunging
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATHA
Fax
N/A
Employees
34
Year Founded
N/A

Company Calendar

Last Earnings
5/12/2022
Today
7/05/2022
Next Earnings (Estimated)
8/15/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$27.60
High Stock Price Forecast
$51.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+707.0%
Consensus Rating
Hold
Rating Score (0-4)
2.33333333333333
Research Coverage
6 Analysts

Profitability

Net Income
$-54,850,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$8.60 per share

Miscellaneous

Free Float
32,028,000
Market Cap
$128.73 million
Optionable
Not Optionable
Beta
3.92














Athira Pharma Frequently Asked Questions

Should I buy or sell Athira Pharma stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athira Pharma in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Athira Pharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATHA, but not buy additional shares or sell existing shares.
View analyst ratings for Athira Pharma
or view top-rated stocks.

What is Athira Pharma's stock price forecast for 2022?

6 brokerages have issued 1-year target prices for Athira Pharma's stock. Their ATHA stock forecasts range from $5.00 to $51.00. On average, they predict Athira Pharma's share price to reach $27.60 in the next year. This suggests a possible upside of 707.0% from the stock's current price.
View analysts' price targets for Athira Pharma
or view top-rated stocks among Wall Street analysts.

How has Athira Pharma's stock price performed in 2022?

Athira Pharma's stock was trading at $13.03 at the beginning of 2022. Since then, ATHA shares have decreased by 73.8% and is now trading at $3.42.
View the best growth stocks for 2022 here
.

When is Athira Pharma's next earnings date?

Athira Pharma is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our earnings forecast for Athira Pharma
.

How were Athira Pharma's earnings last quarter?

Athira Pharma, Inc. (NASDAQ:ATHA) issued its quarterly earnings results on Thursday, May, 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by $0.01.
View Athira Pharma's earnings history
.

Who are Athira Pharma's key executives?

Athira Pharma's management team includes the following people:
  • Dr. Mark J. Litton M.B.A., MBA, Ph.D., Pres, CEO & Director (Age 54, Pay $726.32k)
  • Ms. Rachel P. Lenington M.B.A., Chief Operating Officer
  • Mr. Mark F. Worthington J.D., Gen. Counsel & Corp. Sec.
  • Ms. Glenna K. Mileson, Chief Financial Officer (Age 63)
  • Mr. Robert Renninger, Director of Accounting & Reporting
  • Ms. Julie Rathbun, Head of Investor Relations
  • Dr. Kevin Church Ph.D., Exec. VP of Research (Age 37)

What other stocks do shareholders of Athira Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Athira Pharma investors own include GW Pharmaceuticals (GWPH), Intel (INTC), Lumentum (LITE), NIO (NIO), NVIDIA (NVDA), Boeing (BA), Alibaba Group (BABA), Beyond Meat (BYND), Delta Air Lines (DAL) and Extreme Networks (EXTR).

When did Athira Pharma IPO?

(ATHA) raised $160 million in an initial public offering on Friday, September 18th 2020. The company issued 10,000,000 shares at $15.00-$17.00 per share. Goldman Sachs, Jefferies and Stifel served as the underwriters for the IPO and JMP Securities was co-manager.

What is Athira Pharma's stock symbol?

Athira Pharma trades on the NASDAQ under the ticker symbol "ATHA."

How do I buy shares of Athira Pharma?

Shares of ATHA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Athira Pharma's stock price today?

One share of ATHA stock can currently be purchased for approximately $3.42.

How much money does Athira Pharma make?

Athira Pharma (NASDAQ:ATHA) has a market capitalization of $128.73 million. The company earns $-54,850,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis.

How many employees does Athira Pharma have?

Athira Pharma employs 34 workers across the globe.

How can I contact Athira Pharma?

The official website for Athira Pharma is athira.com. The company can be reached via phone at 425-620-8501 or via email at ir@athira.com.

This page (NASDAQ:ATHA) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.